Cardiolipin modulation represents a promising therapeutic strategy for obesity management by either restoring mitochondrial function or mildly reducing mitochondrial coupling to increase energy expenditure.
Does cardiolipin modulation improve mitochondrial function or increase energy expenditure in obesity?
Cardiolipin modulation represents a promising therapeutic target for managing obesity and associated mitochondrial dysfunction.
Cardiolipin is a specific phospholipid of the mitochondrial inner membrane that participates in many aspects of its organization and function, hence promoting proper mitochondrial ATP production. Here, we review recent data that have investigated alterations of cardiolipin in different tissues in the context of obesity and the related metabolic syndrome. Data relating perturbations of cardiolipin content or composition are accumulating and suggest their involvement in mitochondrial dysfunction in tissues from obese patients. Conversely, cardiolipin modulation is a promising field of investigation in a search for strategies for obesity management. Several ways to restore cardiolipin content, composition or integrity are emerging and may contribute to the improvement of mitochondrial function in tissues facing excessive fat storage. Inversely, reduction of mitochondrial efficiency in a controlled way may increase energy expenditure and help fight against obesity and in this perspective, several options aim at targeting cardiolipin to achieve a mild reduction of mitochondrial coupling. Far from being just a victim of the deleterious consequences of obesity, cardiolipin may ultimately prove to be a possible weapon to fight against obesity in the future.
Prola et al. (Wed,) conducted a review in Obesity and metabolic syndrome. Cardiolipin modulation was evaluated. Cardiolipin modulation represents a promising therapeutic strategy for obesity management by either restoring mitochondrial function or mildly reducing mitochondrial coupling to increase energy expenditure.